Validation and implementation of targeted capture and sequencing for the detection of actionable mutation, copy number variation, and gene rearrangement in clinical cancer specimens.
about
Germline ETV6 mutations in familial thrombocytopenia and hematologic malignancyPrecision medicine in NSCLC and pathology: how does ALK fit in the pathway?Translating cancer genomes and transcriptomes for precision oncologyNot All Next Generation Sequencing Diagnostics are Created Equal: Understanding the Nuances of Solid Tumor Assay Design for Somatic Mutation DetectionAdvances in the Molecular Analysis of Soft Tissue Tumors and Clinical ImplicationsGenomic assays for Epstein-Barr virus-positive gastric adenocarcinomaClinical tumor sequencing: opportunities and challenges for precision cancer medicineGermline and somatic mutations in homologous recombination genes predict platinum response and survival in ovarian, fallopian tube, and peritoneal carcinomasTechnological considerations for genome-guided diagnosis and management of cancerMolecular Diagnostics for Precision Medicine in Colorectal Cancer: Current Status and Future PerspectiveClinicians' expectations for gene-driven cancer therapyAge-related mutations associated with clonal hematopoietic expansion and malignanciesPioneering geneticist Mary-Claire King receives the 2014 Lasker~Koshland Special Achievement Award in Medical ScienceAssessing copy number alterations in targeted, amplicon-based next-generation sequencing data.Ioncopy: a novel method for calling copy number alterations in amplicon sequencing data including significance assessment.The impact of tumor profiling approaches and genomic data strategies for cancer precision medicine.Molecular digital pathology: progress and potential of exchanging molecular data.Good Laboratory Standards for Clinical Next-Generation Sequencing Cancer Panel Tests.Complex MSH2 and MSH6 mutations in hypermutated microsatellite unstable advanced prostate cancerDetection of minimal residual disease in NPM1-mutated acute myeloid leukemia by next-generation sequencing.Next-Generation Sequencing in Oncology: Genetic Diagnosis, Risk Prediction and Cancer Classification.Comparison of custom capture for targeted next-generation DNA sequencingGenomic analysis of bone marrow failure and myelodysplastic syndromes reveals phenotypic and diagnostic complexityColon and endometrial cancers with mismatch repair deficiency can arise from somatic, rather than germline, mutations.Assessing the clinical value of targeted massively parallel sequencing in a longitudinal, prospective population-based study of cancer patients.Development and validation of the JAX Cancer Treatment Profile™ for detection of clinically actionable mutations in solid tumors.Multi-institutional Oncogenic Driver Mutation Analysis in Lung Adenocarcinoma: The Lung Cancer Mutation Consortium Experience.Memorial Sloan Kettering-Integrated Mutation Profiling of Actionable Cancer Targets (MSK-IMPACT): A Hybridization Capture-Based Next-Generation Sequencing Clinical Assay for Solid Tumor Molecular Oncology.Amplicon sequencing of colorectal cancer: variant calling in frozen and formalin-fixed samples.Identification of major factors associated with failed clinical molecular oncology testing performed by next generation sequencing (NGS).Evaluation of Hybridization Capture Versus Amplicon-Based Methods for Whole-Exome SequencingMolecular markers predictive of chemotherapy response in colorectal cancerClinical Validation and Implementation of a Targeted Next-Generation Sequencing Assay to Detect Somatic Variants in Non-Small Cell Lung, Melanoma, and Gastrointestinal Malignancies.A wide spectrum of EGFR mutations in glioblastoma is detected by a single clinical oncology targeted next-generation sequencing panelBuilding a Robust Tumor Profiling Program: Synergy between Next-Generation Sequencing and Targeted Single-Gene TestingPatterns and functional implications of rare germline variants across 12 cancer typesInherited mutations in cancer susceptibility genes are common among survivors of breast cancer who develop therapy-related leukemia.Deep sequencing with intronic capture enables identification of an APC exon 10 inversion in a patient with polyposis.A targeted next-generation sequencing method for identifying clinically relevant mutation profiles in lung adenocarcinoma.Broad, Hybrid Capture-Based Next-Generation Sequencing Identifies Actionable Genomic Alterations in Lung Adenocarcinomas Otherwise Negative for Such Alterations by Other Genomic Testing Approaches
P2860
Q24314163-B1297FA0-3461-4C01-8FF3-23F91521A80BQ26738390-197156CC-1CAA-456B-9A33-8B6D2AEE79DEQ26777081-839F87A2-F6BF-464F-81E9-88B31155159EQ26801745-7370DAC1-7427-4E74-B19D-A365C2306C55Q27021848-76EF0912-A4D2-49E6-AA9B-D435F3B68C24Q27024034-F02CD9C7-1D42-4E97-9179-8B05C2F34B90Q27027942-5E4DBD05-7977-47EE-A728-DE347593DB13Q27852671-3E7FF760-1C57-48DD-970E-04573978FBF7Q28066706-D2157853-A8F1-46DE-9BA7-52EBC91462A6Q28070038-20BD477B-F167-4F07-9738-B5121C78AF59Q28083844-9608F6CA-D162-4986-B7C7-AE81E8977866Q28387160-B1118BA1-5F90-48E2-B301-418C0129B394Q28654820-D8A2DB1E-578F-4D5E-BAC2-49C936D3B93EQ30874026-C7E6793A-39D2-41E6-A7D6-E1EC3B1D9CF8Q31048851-56C81941-FB5A-4584-8831-5D7CE0F5E029Q31117752-46A11235-1082-4E7E-8983-B5C8798B3429Q31118370-37C13D98-2EC3-43F8-AA87-98FB34537CD7Q33729699-7381D585-7374-429C-A7C2-CA4B62CD05CAQ34252397-248C6608-BBF4-4BA0-9EF4-34E76529C34AQ34364350-A8FC0DA4-5E23-4A78-999B-85C2946397A2Q34550417-13274293-EE17-4228-8DBF-0FF444B45F0EQ34786626-A9B16CE5-1946-4296-A6E8-E13AE471B18BQ34798007-93BD6CF8-94DD-459D-9A95-436251B93C74Q34959257-D4A8B542-55EF-4770-895C-976DC06215D7Q35475492-4952EACF-BF6A-44F8-AD43-1BD335320BB1Q35538750-09DEBC81-5CB7-4F3A-8111-8B2284118678Q35541778-6096E634-8F4F-4696-9894-6AC53763385CQ35584856-9139BBAC-79C7-462F-A284-772A3EE00DCBQ35641264-5A042921-7A36-48B8-8945-5B38F05F0C39Q35662768-FC61D922-FCE8-4F6E-AF91-432F1A7E75F0Q35674525-800496FB-8678-4D0F-B7F0-C932CE2C08CBQ35761956-BE65B33B-5AD2-4E43-9926-265AE0199215Q35901968-19515A16-41B0-4CDB-B6B2-59802AE15DCCQ35963284-C54D4DC5-F8E8-4594-B3F6-5B7FAC0380E7Q35979104-3FBEDF28-17C5-4582-A9B2-A6F5D97B7E75Q36437964-73FE66C5-18D2-4FC9-9049-9397C53FDF93Q36450186-2618BE30-41F4-4DD7-8DEF-C4BD5F5D9E25Q36576392-3F6777CF-D4BA-46DE-8006-738719A13444Q36645600-1C29A918-9E32-4E3F-8778-BE26D987C220Q37028777-3E5FB495-BD6F-42B0-BB60-F1E9EF69F45B
P2860
Validation and implementation of targeted capture and sequencing for the detection of actionable mutation, copy number variation, and gene rearrangement in clinical cancer specimens.
description
2013 nî lūn-bûn
@nan
2013年の論文
@ja
2013年論文
@yue
2013年論文
@zh-hant
2013年論文
@zh-hk
2013年論文
@zh-mo
2013年論文
@zh-tw
2013年论文
@wuu
2013年论文
@zh
2013年论文
@zh-cn
name
Validation and implementation ...... in clinical cancer specimens.
@en
type
label
Validation and implementation ...... in clinical cancer specimens.
@en
prefLabel
Validation and implementation ...... in clinical cancer specimens.
@en
P2093
P2860
P1476
Validation and implementation ...... in clinical cancer specimens.
@en
P2093
Andrew Adey
Brent Wood
Christina Smith
Colin C Pritchard
Jane E Churpek
Jonathan F Tait
Karen Koehler
Kari Stricker
Keith D Eaton
P2860
P356
10.1016/J.JMOLDX.2013.08.004
P577
2013-11-02T00:00:00Z